A new approach for potential drug target discovery through in silico metabolic pathway analysis using Trypanosoma cruzi genome information.
The current drug options for the treatment of chronic Chagas disease have not been sufficient and high hopes have been placed on the use of genomic data from the human parasite Trypanosoma cruzi to identify new drug targets and develop appropriate treatments for both acute and chronic Chagas disease. However, the lack of a complete assembly of the genomic sequence and the presence of many predicted proteins with unknown or unsure functions has hampered our complete view of the parasite's metabolic pathways. Moreover, pinpointing new drug targets has proven to be more complex than anticipated and has revealed large holes in our understanding of metabolic pathways and their integrated regulation, not only for this parasite, but for many other similar pathogens. Using an in silicocomparative study on pathway annotation and searching for analogous and specific enzymes, we have been able to predict a considerable number of additional enzymatic functions in T. cruzi. Here we focus on the energetic pathways, such as glycolysis, the pentose phosphate shunt, the Krebs cycle and lipid metabolism. We point out many enzymes that are analogous to those of the human host, which could be potential new therapeutic targets.
Laboratório de Genômica Funcional e Bioinformática, Instituto Oswaldo Cruz-Fiocruz, Rio de Janeiro, Brasil.
Marcelo
M
Alves-Ferreira
Ana Carolina Ramos
AC
Guimarães
Priscila Vanessa da Silva Zabala
PV
Capriles
Laurent E
LE
Dardenne
Wim M
WM
Degrave
D055808:Drug Discovery; D018503:Genome, Protozoan / Q000187:drug effects / Q000235:genetics*; D006801:Humans; D053858:Metabolic Networks and Pathways / Q000235:genetics*; D014344:Trypanocidal Agents; D014349:Trypanosoma cruzi / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*
D014344:Trypanocidal Agents